The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

i am a healthcare professional i am not a healthcare professional
JANUVIA® (sitagliptin)

Nationwide formulary access

Greater than 80% of patients in commercial plans are covered at the lowest branded co-pay without prior authorizations.a,b

For Medicare Part D beneficiaries, approximately 90% are covered at the lowest branded co-pay without prior authorizations.a,b

Use the tool below to find local formulary coverage information.

1
2
3

aFormulary data provided by Fingertip Formulary®, April, 2014.
Percentages based on current enrollment.
bAmong oral antidiabetics and glucagon-like peptide-1s.
cIncludes commercial, Medicaid, and Medicare Part D plans.

Formulary status is believed to be accurate at the time of update but cannot be guaranteed. Formulary status for national plans may not reflect plan variation at the local level.

Updated formulary status information for Medicare plans may be available from the Centers for Medicare & Medicaid Services: www.medicare.gov.

View your results below for the county you chose in step 2. Results are listed alphabetically.


A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Selected Important Risk Information

Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or chronic, when receiving JANUMET.

Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin. Therefore, in patients in whom any such study is planned, JANUMET should be temporarily discontinued at the time of or before the procedure, withheld for 48 hours subsequent to the procedure, and reinstituted only after renal function has been re-evaluated and found to be normal.

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUMET or any other oral antidiabetic drug.

Please read the Boxed Warning about lactic acidosis